120 related articles for article (PubMed ID: 9816233)
1. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.
Zhang W; Piatyszek MA; Kobayashi T; Estey E; Andreeff M; Deisseroth AB; Wright WE; Shay JW
Clin Cancer Res; 1996 May; 2(5):799-803. PubMed ID: 9816233
[TBL] [Abstract][Full Text] [Related]
2. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of telomerase activity levels in acute leukemia.
Ohyashiki JH; Ohyashiki K; Iwama H; Hayashi S; Toyama K; Shay JW
Clin Cancer Res; 1997 Apr; 3(4):619-25. PubMed ID: 9815729
[TBL] [Abstract][Full Text] [Related]
4. [Telomere and telomerase in human cancer].
Hiyama K; Hiyama E; Ishioka S; Yamakido M
Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
[TBL] [Abstract][Full Text] [Related]
5. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes.
Swiggers SJ; Kuijpers MA; de Cort MJ; Beverloo HB; Zijlmans JM
Genes Chromosomes Cancer; 2006 Mar; 45(3):247-56. PubMed ID: 16281260
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of telomerase activity and telomere length in acute myelogenous leukemia].
Liu L; Sun B; Liang Y
Zhonghua Xue Ye Xue Za Zhi; 2001 Nov; 22(11):592-4. PubMed ID: 11855149
[TBL] [Abstract][Full Text] [Related]
9. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in patients with chronic myeloid leukemia and lymphoma.
Bitisik O; Yavuz S; Yasasever V; Dalay N
Res Commun Mol Pathol Pharmacol; 2000; 107(1-2):3-12. PubMed ID: 11334367
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
12. A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias.
Tatematsu K; Nakayama J; Danbara M; Shionoya S; Sato H; Omine M; Ishikawa F
Oncogene; 1996 Nov; 13(10):2265-74. PubMed ID: 8950994
[TBL] [Abstract][Full Text] [Related]
13. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities.
Hartmann U; Brümmendorf TH; Balabanov S; Thiede C; Illme T; Schaich M
Haematologica; 2005 Mar; 90(3):307-16. PubMed ID: 15749662
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
Tauchi T; Nakajima A; Sashida G; Shimamoto T; Ohyashiki JH; Abe K; Yamamoto K; Ohyashiki K
Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620
[TBL] [Abstract][Full Text] [Related]
15. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
16. Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase.
Nowak T; Januszkiewicz D; Zawada M; Pernak M; Lewandowski K; Rembowska J; Nowicka K; Mankowski P; Nowak J
Oncol Rep; 2006 Aug; 16(2):301-5. PubMed ID: 16820907
[TBL] [Abstract][Full Text] [Related]
17. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4.
Preisler HD; Li B; Yang BL; Huang RW; Devemy E; Venugopal P; Tao M; Chopra H; Gregory SA; Adler S; Sivaraman S; Toofanfard P; Jajeh A; Galvez A; Robin E
Clin Cancer Res; 2000 Mar; 6(3):807-12. PubMed ID: 10741700
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of telomerase limits the growth of human cancer cells.
Hahn WC; Stewart SA; Brooks MW; York SG; Eaton E; Kurachi A; Beijersbergen RL; Knoll JH; Meyerson M; Weinberg RA
Nat Med; 1999 Oct; 5(10):1164-70. PubMed ID: 10502820
[TBL] [Abstract][Full Text] [Related]
19. Synergistic down-regulation of telomerase activity and hTERT mRNA expression by combination of retinoic acid and GM-CSF in human myeloblastic leukemia ML-1 cells.
Mano Y; Shimizu T; Tanuma S; Takeda K
Anticancer Res; 2000; 20(3A):1649-52. PubMed ID: 10928085
[TBL] [Abstract][Full Text] [Related]
20. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.
Kim JH; Kim JH; Lee GE; Kim SW; Chung IK
Biochem J; 2003 Jul; 373(Pt 2):523-9. PubMed ID: 12689331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
